Other formats:
BibTeX
LaTeX
RIS
@article{1725116,
author = {Smidova, V and Michalek, P and Goliášová, Zita and Eckschlager, T and Hodek, P and Adam, V and Heger, Z},
article_location = {Lake Haven},
article_number = {4},
doi = {http://dx.doi.org/10.7150/thno.48662},
keywords = {Bioavailability; Drug delivery; Nanotechnology; Targeted therapy},
language = {eng},
issn = {1838-7640},
journal = {Theranostics},
title = {Nanomedicine of tyrosine kinase inhibitors},
volume = {11},
year = {2021}
}
TY - JOUR
ID - 1725116
AU - Smidova, V - Michalek, P - Goliášová, Zita - Eckschlager, T - Hodek, P - Adam, V - Heger, Z
PY - 2021
TI - Nanomedicine of tyrosine kinase inhibitors
JF - Theranostics
VL - 11
IS - 4
SP - 1546-1567
EP - 1546-1567
PB - Ivyspring International Publisher
SN - 18387640
KW - Bioavailability
KW - Drug delivery
KW - Nanotechnology
KW - Targeted therapy
N2 - Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials. Some nanocarrier properties provide improvement of drug efficacy, reduce the incidence of adverse events, enhance drug bioavailability, helps to overcome the blood-brain barrier, increase drug stability or allow for specific delivery of TKIs to the diseased cells. Moreover, nanotechnology can bring new perspectives into combination therapy, which can be highly efficient in connection with TKIs. Lastly, nanotechnology in combination with TKIs can be utilized in the field of theranostics, i.e. for simultaneous therapeutic and diagnostic purposes. The review provides a comprehensive overview of advantages and future prospects of conjunction of nanotransporters with TKIs as a highly promising approach to anticancer therapy.
ER -
SMIDOVA, V, P MICHALEK, Zita GOLIÁŠOVÁ, T ECKSCHLAGER, P HODEK, V ADAM and Z HEGER. Nanomedicine of tyrosine kinase inhibitors. \textit{Theranostics}. Lake Haven: Ivyspring International Publisher, 2021, vol.~11, No~4, p.~1546-1567. ISSN~1838-7640. Available from: https://dx.doi.org/10.7150/thno.48662.
|
